Literature DB >> 7992461

Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers.

V Rattan1, H Sidhu, S Vaidyanathan, S K Thind, R Nath.   

Abstract

A combined supplement of magnesium oxide (300 mg/day) and pyridoxine.HCl (10 mg/day) was given p.o. to 16 recurrent calcium oxalate (CaOx) stone formers, and its therapeutic efficacy was biochemically evaluated by measuring various parameters of blood (Na, K, Mg, urea, creatinine, calcium, phosphate, uric acid, alanine transaminase, aspartate transaminase and alkaline phosphatase) and urine (volume, pH, creatinine, Na, K, Mg, uric acid, calcium, phosphate, oxalate and citrate) at 0, 30, 60, 90 and 120 days of treatment. Serum Mg significantly (P < 0.01) increased after 30 days of treatment and remained constant thereafter while other blood parameters were unaltered. Combined treatment led to a significant increase in the urinary excretion of Mg and citrate over pretreatment values while oxalate excretion showed a gradual and significant decline during the therapy. The results confirmed the efficacy of MgO-pyridoxine supplementation in terms of changes in urinary excretion of lithogenic and inhibitory components, leading to a significant (P < 0.01) decrease in CaOx risk index from 0.09 +/- 0.04 at 0 day to 0.05 +/- 0.02 after 120 days of treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992461     DOI: 10.1007/BF00571844

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  27 in total

1.  Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis.

Authors:  E Takasaki
Journal:  Invest Urol       Date:  1975-01

2.  The action of pyridoxine in primary hyperoxaluria.

Authors:  D A Gibbs; R W Watts
Journal:  Clin Sci       Date:  1970-02       Impact factor: 6.124

3.  Magnesium therapy for recurring calcium oxalate urinary calculi.

Authors:  I Melnick; R R Landes; A A Hoffman; J F Burch
Journal:  J Urol       Date:  1971-01       Impact factor: 7.450

4.  Oxalate metabolism in magnesium-deficient rats.

Authors:  V Rattan; S K Thind; R K Jethi; H Sidhu; R Nath
Journal:  Magnes Res       Date:  1993-06       Impact factor: 1.115

5.  Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts.

Authors:  K Sakhaee; M Nicar; K Hill; C Y Pak
Journal:  Kidney Int       Date:  1983-09       Impact factor: 10.612

6.  Primary oxalosis: clinical and biochemical response to high-dose pyridoxine therapy.

Authors:  E J Will; O L Bijvoet
Journal:  Metabolism       Date:  1979-05       Impact factor: 8.694

7.  Effect of pyridoxine supplementation on recurrent stone formers.

Authors:  M S Murthy; S Farooqui; H S Talwar; S K Thind; R Nath; L Rajendran; B C Bapna
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-09

8.  An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease.

Authors:  H G Tiselius
Journal:  Clin Chim Acta       Date:  1982-07-15       Impact factor: 3.786

9.  Vitamin B6 deficiency as related to oxalate-synthesizing enzymes in growing rats.

Authors:  M S Murthy; H S Talwar; S K Thind; R Nath
Journal:  Ann Nutr Metab       Date:  1982       Impact factor: 3.374

10.  Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis.

Authors:  C D Fetner; D E Barilla; J Townsend; C Y Pak
Journal:  J Urol       Date:  1978-10       Impact factor: 7.450

View more
  6 in total

1.  Effect of blind treatment on stone disease.

Authors:  Y M Fazil Marickar; Abiya Salim; Adarsh Vijay
Journal:  Urol Res       Date:  2009-12-08

2.  Vitamin B6 intake and the risk of incident kidney stones.

Authors:  Pietro Manuel Ferraro; Eric N Taylor; Giovanni Gambaro; Gary C Curhan
Journal:  Urolithiasis       Date:  2017-07-03       Impact factor: 3.436

3.  Vitamin B6 metabolites in idiopathic calcium stone formers: no evidence for a link to hyperoxaluria.

Authors:  Agnes Kaelin; Jean-Paul Casez; Philippe Jaeger
Journal:  Urol Res       Date:  2003-11-20

4.  Alpha-enolase on apical surface of renal tubular epithelial cells serves as a calcium oxalate crystal receptor.

Authors:  Kedsarin Fong-Ngern; Visith Thongboonkerd
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

5.  Diet-Derived Antioxidants and Risk of Kidney Stone Disease: Results From the NHANES 2007-2018 and Mendelian Randomization Study.

Authors:  Zhongyu Jian; Menghua Wang; Xi Jin; Hong Li; Kunjie Wang
Journal:  Front Nutr       Date:  2021-12-21

6.  Drosophila melanogaster as a function-based high-throughput screening model for antinephrolithiasis agents in kidney stone patients.

Authors:  Sohrab N Ali; Thamara K Dayarathna; Aymon N Ali; Tijani Osumah; Mohamed Ahmed; Tyler T Cooper; Nicholas E Power; Dongxing Zhang; Dajung Kim; Rachel Kim; Andre St Amant; Jinqiang Hou; Thomas Tailly; Jun Yang; Len Luyt; Paul A Spagnuolo; Jeremy P Burton; Hassan Razvi; Hon S Leong
Journal:  Dis Model Mech       Date:  2018-11-16       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.